Key facts
- It has raised $370K.
- Notable investors include Illinois Institute of Technology, Illinois Science & Technology Coalition.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Biagon
- ·The full record, as it builds
Funding rounds
No funding rounds for Biagon are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biagon
Developer of a GPCR drug discovery platform designed to enable precise control of cell signaling through biased agonists. The company offers machine learning-driven ligand identification, differentiated signaling profile analysis, discovery of functionally selective compounds, enabling pharmaceutical companies, biotechnology researchers to develop targeted therapies with improved therapeutic windows.
- Sector
- Healthcare
- HQ
- Chicago, IL, United States
- Founded
- 2024
- Employees
- 5
- Website
- biagoninc.com/
- Ownership
- Privately Held (backing)
Biagon doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biagon shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biagon in its N-PORT filings yet. We sweep new filings monthly.